Former CEO of Ranbaxy, Brian Tempest, expects more pricing pressure to come in US under Donald Trump administration. Speaking to CNBCTV-18 on the sidelines of the IIFL Conference in Mumbai, he added that Trump’s policies could actually lead to fall in prices of Indian pharma products in the US as he could permit getting generics from Canada or Europe.
“There is a lot of pressure that is building on the Indian pharma industry in particular due to the change of the President of USA. He is going to lead a lot more pressure on pricing in America,” he said.As per Trump's health policy, he is happy to bring medicines from other countries. He could bring generics from Canada or Europe or he could introduce tendering of these products, added Tempest. This will lead to significant downfall in the prices of Indian pharma products in America.
One of the key things Trump will focus on is to 'Make in America' and will encourage companies to build their organisations there and to employ americans, he said. To know more, watch video...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
